Miltenyi Biotec, Gmbh

Miltenyi Biotec B.v. Co., Kg

Memorec Biotec Gmbh

Memorec Medical Molecular Research Cologne Stoffel Gmbh

Miltenyi Biotec B.v. & Co. Kg

Andreas Bosio

Stefan Miltenyi

Olaf Hardt

Dominik Eckardt

Eiad Kabaha

Andrzej Dzionek

Ralf-Peter Peters

Thomas Rothmann

Mario Assenmacher

Andrew Kaiser

Kristin Becker

Sebastian Knöbel

Heinrich Spiecker

Wolfgang Stoeters

Thomas Rockel

Timo Adams

Wolfgang Stoters

Carsten Poggel

Jutta Kollet

Robert Pinard

Stefan Tomiuk

Seiyu Hosono

Hansueli Meyer

Agnete Kirkeby

Stefan Wild

Wilhelm Stoffel

Malin Parmar

Marion Jurk

Melanie Jungblut

David Joel Agorku

Ryan Hindman

Chris Nehme

Emily Neil

Andrej Smiyakin

Jan Keseberg

Markus Stoffel

Anne Maria Wiencierz

David Agorku

Serena Barral

Daniela Lehnen

Andrea Aloia

Andrea VÖLKEL

Sebastian KNÖBEL

Sandra Jungpertz

Olaf Thorsten Hardt

Wolfgang STÖTERS

Ute Bissels

Herr Eiad Kabaha

Kristin Noack

Eleni Papanikolaou

The invention is directed to a conjugate having the general formula (I)X—P—YB  (I) Further, the invention is directed to a library of such conjugates and a method of detecting target cells utilizing the conjugates or the library of conjugates.

Conjugates having an enzymmatically releasable detection moiety and a barcode moiety

Microscopy imaging that allow for multiple mRNAs, proteins and metabolites to be spatially resolved at a subcellular level provides valuable molecular information which is a crucial factor for understanding tissue heterogeneity as for example within the tumor micro environment. The current invention describes a method (SUMI-Seq) which combines the use of Spatial Unique Molecular Identifier in situ sequencing and in vitro sequencing of rolonies derived from rolling circle amplification from padlock oligonucleotides targeting portion of RNA or cDNA transcript at a subcellular level with less limitation in the amount of transcripts and the length of the sequence that can be analyzed. Apart from padlocks oligonucleotides, the SUMI-Seq method can also be applied using circular oligonucleotides to spatially resolve proteins and metabolites to provide multiomics results.

Method and instrumentation for spatial multiomics using SUMI-technology

The present invention provides the use of a nucleic acid encoding SOCS1 for enhancing the efficacy of introducing at least one nucleic acid of interest into a cell; a method of repeated transfection of a cell with at least one nucleic acid of interest comprising the steps of adding a) nucleic acid encoding SOCS1, and simultaneously or subsequently b) at least one nucleic acid of interest encoding at least one polypeptide of interest, wherein at least step b) is repeated at least once; and a method of electroporation of a cell with at least one nucleic acid of interest comprising the steps of adding to the cell a) a nucleic acid encoding SOCS1, and simultaneously or subsequently b) said at least one nucleic of interest. The at least one nucleic acid of interest and the nucleic acid encoding SOCS1 may be mRNAs, wherein each of said mRNAs has a poly(A) tail at its 3' end comprising at least 200 adenines.

In vitro method of reprogramming fibroblast cells into induced pluripotent stem cells by transcription factors mRNAs co-transfected with SOCS1 mRNA wherein the mRNAs have a poly-A tail of at least 2000 adenines

The present invention provides a cell culture for obtaining an epithelial organoid, the cell culture comprising i) epithelial stem cells, or tissue fragments comprising said epithelial stem cells, ii) a basal medium for animal or human cells, iii) a Bone Morphogenetic Protein (BMP) inhibitor, iv) a mitogenic growth factor selected from the group consisting of epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha), basic fibroblast growth factor (bFGF), brain-derived neurotrophic factor (BDNF) and keratinocyte growth factor (KGF), v) at least one soluble culture enhancer, wherein said at least one culture enhancer induces correct polarization of the cells in said cell culture within the developing organoid such as a laminin/entactin complex or entactin, and vi) a Wnt agonist if said epithelial stem cells, or tissue fragments comprising said epithelial stem cells are healthy cells, wherein said at least one soluble culture enhancer in said cell culture is a laminin/entactin complex in a concentration between 0.2 mg/ml and 3.4 mg/ml. A cell culture medium, an in-vitro method for obtaining an epithelial organoid, and an epithelial organoid obtained by said method are also disclosed.

Cell culture medium and method for generation of epithelial organoids from epithelial stem cells

The present invention is directed to ligand like a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for one or more antigens selected from the group consisting of CLA, CD142, CD73, CD49c, CD66c, CD104, CD318 and TSPAN8; cell populations expressing such CARs and the use of the cell populations for cancer therapy.

Chimeric antigen receptor specific for tumor cells

The present invention provides an in-vitro method for analyzing a cell composition comprising human floorplate mesDA progenitor cells, the method comprising a) contacting the cells of said cell composition or the cells of a sample thereof with antigen binding molecules specific for the antigens FOXA2, OTX2, PAX6, and NKX6.1, thereby labeling the cells of said cell composition or of said sample, b) determining the percentage of said cells that are labelled with said antigen binding molecules for each of said antigens, and wherein the cells of said cell composition qualify as human floorplate mesDA progenitor cells if the protein expression profile of said cells is: 80-100% of said cells are positive for FOXA2, 80-100% of said cells are positive for OTX2, less than 10% of said cells are positive for PAX6, and less than 10% of said cells are positive for NKX6.1. A kit comprising said antigen binding molecules for use in said method is also provided.

Method and kit for single cell protein expression profiling of floorplate mesencephalic dopaminergic progenitor cells

The present invention discloses an in vitro method for the generation of a cell composition comprising or consisting of ventral midbrain dopaminergic progenitor cells from a cell composition comprising pluripotent and/or multipotent stem cells, the method comprising the steps of A) differentiating said pluripotent and/or multipotent stem cells into ventral dopaminergic progenitor cells, thereby generating a cell composition comprising ventral dopaminergic progenitor cells comprising ventral midbrain dopaminergic progenitor cells and ventral hindbrain dopaminergic progenitor cells, and B) Enriching CD117 positive cells from said cell composition comprising ventral dopaminergic progenitor cells by using an antigen binding molecule specific for the CD117 antigen, thereby generating said cell composition comprising or consisting of ventral midbrain dopaminergic progenitor cells. Cell compositions obtainable by said method are also disclosed.

Method for the generation of a cell composition ventral midbrain patterned dopaminergic progenitor cells

The invention is directed to a slide chamber comprising a top member (), a fluidic seal (), a transparent closure member () and base member () wherein the top member () is provided with at least one examination chamber () and a plurality of openings () positioned at two sides of the cover member outside of the examination chamber (); and the base member () is provided with interconnecting means () complementary to the openings () of the top member characterized in that the interconnecting means () of the base member () and the openings () of the top member () are configured to mechanically interlock with each other by lateral movement thereby pressing the top member () against the transparent closure () member in a water-tight manner.

Slide chamber

The present invention provides a method for generation, isolation, detection and/or analysis of cardiomyocytes derived from a starting cell composition comprising pluripotent and/or multipotent stem cells, the method comprising the steps a) differentiating said pluripotent and/or multipotent stem cells into cardiovascular cells, thereby generating a sample comprising cardiomyocytes and non-cardiomyocytes; and b) labeling the non-cardiomyocytes of said sample with more than one antibody or antigen binding fragment thereof specific for antigens of non-cardiomyocytes and c) depleting said labeled non-cardiomyocytes from said sample; and optionally d) labeling the cardiomyocytes of said sample with at least one antibody or antigen binding fragment thereof specific for antigen(s) of cardiomyocytes; and e) enriching said labeled cardiomyocytes and detecting and isolating cardiomyocyte subtypes derived from said pluripotent and/or multipotent stem cells.

Process for generation, identification and isolation of human pluripotent stem cell-derived cardiomyocytes and cardiomyocyte subpopulations

The invention is directed to a Perfusion device for biological tissues comprising Use of the perfusion device in a process for disaggregation of a biological tissue to yield target cells.

Process and device for isolating cells from biological tissue

The present invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain specific for SSEA4, a population of engineered cells expressing said CARs, and a pharmaceutical composition comprising said genetically modified cells expressing said CARs. The pharmaceutical composition may be for use of the treatment of cancer in a subject suffering from cancer, wherein at least a subpopulation of the cancerous cells of said cancer expresses SSEA4.

Chimeric antigen receptor specific for SSEA4 antigen

The present invention provides a method for generation of a cell composition of mesencephalic dopaminergic progenitor cells from a starting cell composition comprising pluripotent and/or multipotent stem cells, the method comprising the steps of a) differentiating said pluripotent and/or multipotent stem cells into mesencephalic dopaminergic progenitor cells, thereby generating a cell population comprising mesencephalic dopaminergic progenitor cells and other cells, b) dissociating the differentiated cells of step a) into a single cell suspension, and c) enriching said mesencephalic dopaminergic progenitor cells by using an antigen binding molecule specific for the CD47 antigen for positive selection of said mesencephalic dopaminergic progenitor cells in said single cell suspension. Said method may be performed in a closed cell sample processing system and may be performed in an automated manner.

Method for generation of a cell composition of mesencephalic dopaminergic progenitor cells

A cell strainer for separating particles from a cell suspension, having an upper portion with at least one filter area lying essentially perpendicular to the direction of flow of the suspension and a lower portion adapted to fit into the openings of at least two sample tubes with different sized openings. The lower portion has a first section with shoulders or flanges having the diameter of the opening of a first tube and a second section having an inner and outer wall serving as a receptacle for the neck of a second tube, where the diameter of the first section is larger than the diameter of the second section.

Stackable cell strainer

A process for depleting host cells from a xenograft of human cells on a murine host is disclosed. The process includes fragmenting the xenograft, subjecting the sample to antibodies specific for a murine CD9 epitope coupled to a detection means, depleting the cell suspension from cells bound by the CD9-antibodies using the detection means, and collecting the cells not bound by the CD9-antibodies as target cells.

Depletion of mouse cells for isolation of human cells

Growing community of inventors

Cologne, Germany

Andreas Bosio